Milestone Pharmaceuticals (NASDAQ:MIST) Posts Earnings Results, Misses Expectations By $0.02 EPS

Key Points

• Milestone Pharmaceuticals reported an earnings per share (EPS) of ($0.20) for the quarter, missing analysts' expectations by $0.02.
• The company's stock rose 6.8% during trading, closing at $1.66, despite having a market capitalization of $88.48 million.
• HC Wainwright upgraded the stock to a "buy" rating with a price target of $5.00, reflecting positive sentiment from analysts amidst the earnings miss.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) released its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02), Zacks reports.

Milestone Pharmaceuticals Stock Up 6.8%

MIST traded up $0.11 during trading on Tuesday, reaching $1.66. The stock had a trading volume of 910,431 shares, compared to its average volume of 1,755,175. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $2.75. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 4.06. The stock's 50 day moving average is $1.71 and its two-hundred day moving average is $1.60. The company has a market capitalization of $88.48 million, a price-to-earnings ratio of -2.12 and a beta of 0.52.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price objective on the stock in a research note on Thursday, June 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $7.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. Creative Planning grew its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 74.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,410 shares of the company's stock after buying an additional 10,000 shares during the period. Creative Planning's holdings in Milestone Pharmaceuticals were worth $45,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.